At least one pharmacist attacked every day in 2022: in pharmacies, attacks have increased by 17% in three years

the essential A report from the National Order of Pharmacists indicates that over the past three years, acts of aggression against pharmacists have increased. In 2022, at least one pharmacist was attacked every day in France. It is a “worrying phenomenon” which greatly worries the National Order of Pharmacists. In French pharmacies, assaults have risen … Read more

New Long-Term Data from the CHRYSALIS Study Show Median Progression-Free Survival Not Reached after 33.6 Months of Follow-Up with First-Line Use of RYBREVANT® (amivantamab-vmjw) and Lazertinib Combination Therapy in Patients with Treatment-Naïve EGFR-Mutated Advanced Non-Small Cell Lung Cancer

Further analyses from the Phase 1/1b CHRYSALIS-2 study showed patients with osimertinib pre-treated EGFR-mutated lung cancer who have a MET positive biomarker had an overall response rate of 61 percent and a median PFS of 12.2 months when treated with the chemotherapy-free combination of RYBREVANT® and lazertinib Updated safety analysis from the Phase 1 PALOMA study … Read more

In Bresse, a forest to eat to save the planet

(AFP) – Mahogany leaves, egopod salad, lavatera and daisy flowers, gingerbread with acorn flour…: in Bresse, an edible forest offers everything humans need to feed themselves, while respecting the planet. “Here, what can be eaten? Everything around you”: Fabrice Desjours sweeps away a lush plant chaos made up of tangles of vines, plants and shrubs, … Read more

In Copenhagen, beer to spice up yoga sessions

(AFP) – Do yoga yes, but with a beer: in Denmark, “beer yoga” has its followers, who meet by the dozen in the summer on a quay in the port of Copenhagen. Every other Wednesday, Anne Lund, a sparkling 40-year-old instructor, gathers disciples for an hour of sequences interspersed with sips of beer. “These are … Read more

AMGEN PRESENTS NEW LUMAKRAS® (SOTORASIB) CODEBREAK 200 CNS DATA AT ASCO 2023

LUMAKRAS ® (sotorasib) Demonstrated Delayed Time to CNS Progression, Longer CNS PFS and Higher Intracranial ORR vs Docetaxel in Post-Hoc Analysis of Phase 3 CodeBreaK 200 Trial LUMAKRAS Shows Improved PFS vs Docetaxel Across Key Co-Alteration Subgroups in the Phase 3 CodeBreaK 200 Study LUMAKRAS Plus Vectibix® (panitumumab) and FOLFIRI Combination Show ORR of 55% in Previously Treated … Read more

Servier Presents Transformational Data from Pivotal Phase 3 INDIGO Trial of Vorasidenib in Recurrent or Residual Grade 2 IDH-Mutant Diffuse Glioma

Vorasidenib demonstrated an unprecedented improvement in progression free survival with a median of 27.7 months in patients with residual or recurrent grade 2 glioma with an IDH1/2 mutation; key secondary endpoint of time to next intervention significantly improved in the vorasidenib arm Results presented at the ASCO 2023 plenary session, highlighting significance for patients with … Read more

Phase 3 SWOG Cancer Research Network trial, led by a City of Hope researcher, demonstrates one-year progression-free survival in 94% of patients with Stage 3 or 4 classic Hodgkin lymphoma who received a checkpoint inhibitor combined with chemotherapy

Nivolumab added to AVD chemotherapy expected to become new standard for initial treatment for advanced stage disease in adolescents and adults, based on trial data to be presented at 2023 American Society of Clinical Oncology (ASCO) Annual Meeting Plenary Session LOS ANGELES and PORTLAND, Ore., June 4, 2023 /PRNewswire/ — A Phase 3 trial has … Read more

Jordan is the first country to provide iris recognition for digital transformation services

A strategic partnership between the Jordanian Ministry of Digital Economy and IrisGuard to implement iris recognition technologies for Government digital services delivery AMMAN, Jordan, June 4, 2023 /PRNewswire/ — Today, IrisGuard and the Jordanian Ministry of Digital Economy and Entrepreneurship signed a strategic partnership agreement for the use of iris recognition to enhance access to Governmental and … Read more